Table 3.
Associations between urine cadmium, modeled with and without urine creatinine adjustment, and kidney outcomes in 712 lead workersa
| Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|
| Kidney Outcome | β coeff (95 % CI) | Model r2 | β coeff (95 % CI) | Model r2 | β coeff (95 % CI) | Model r2 |
| Serum Creatinine, mg/dl | ||||||
| Ln-Urine Cadmium μg/g creat. | −0.066 (−0.090, −0.042)# | 0.34 | ||||
| Ln-Urine Cadmium μg/L | −0.066 (−0.091, −0.041)# | 0.34 | −0.018 (−0.032, −0.004)* | 0.31 | ||
| Ln-Urine Creatinine, mg/dl | 0.065 (0.038, 0.093)# | NA | ||||
| Calculated Creatinine Clearance, ml/min | ||||||
| Ln-Urine Cadmium μg/g creat. | 6.3 (3.3, 9.2)# | 0.50 | ||||
| Ln-Urine Cadmium μg/L | 6.6 (3.6, 9.6)# | 0.50 | 2.8 (1.1, 4.5)** | 0.50 | ||
| Ln-Urine Creatinine, mg/dl | −5.1 (−8.4, −1.8)** | NA | ||||
| Est. Glomerular Filtration Rate, ml/min/1.73 m2 | ||||||
| Ln-Urine Cadmium μg/g creat. | 8.7 (5.4, 12.0)# | 0.17 | ||||
| Ln-Urine Cadmium μg/L | 8.7 (5.4, 12.1)# | 0.17 | 2.3 (0.42, 4.2)* | 0.15 | ||
| Ln-Urine Creatinine, mg/dl | −8.6 (−12.3, −4.9)# | NA | ||||
| Measured Creatinine Clearance, ml/min | ||||||
| Ln-Urine Cadmium μg/g creat. | −3.4 (−8.5, 1.7) | 0.24 | ||||
| Ln-Urine Cadmium μg/L | −1.4 (−6.4, 3.6) | 0.29 | 7.1 (4.3, 10.0)# | 0.27 | ||
| Ln-Urine Creatinine, mg/dl | 11.5 (5.9, 17.1)# | NA | ||||
| Ln-NAG, μmol/h/g creatinine | ||||||
| Ln-Urine Cadmium μg/g creat. | 0.27 (0.17, 0.37)# | 0.20 | ||||
| Ln-Urine Cadmium μg/L | 0.26 (0.16, 0.36)# | 0.20 | 0.03 (−0.03, 0.09) | 0.16 | ||
| Ln-Urine Creatinine, mg/dl | −0.31 (−0.42, −0.20)# | NA | ||||
Models also adjusted for age, gender, BMI, work status (current vs. former lead worker), smoking dose [cigarettes per day × years of smoking) in quartiles for current smokers and ex-smoker status, diastolic blood pressure; alcohol consumption (never, former, current); education (< middle school graduate, < high school graduate, high school graduate, > high school), annual income (≤ 10, 10-20, 20-30, 30-40, and > 40 million won), enrollee status (phase I vs. II study entry), and blood and tibia lead.
p-value < 0.05
p-value < 0.01
p-value < 0.001